Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acutrim

This article was originally published in The Tan Sheet

Executive Summary

Health & Nutrition Systems International expects to book revenue by the end of March from its January acquisition of three Acutrim trademarks and outstanding inventory of two natural "ephedrine-free" appetite suppressant formulations for $180,000 from Heritage Brands/Insight Pharmaceuticals. West Palm Beach, Fla.-based HNS, which markets weight management and body building products such as Carb Cutter, Thin Tab and Carbolizer in gyms, health food stores and drug chains, purchased only the inventory for Acutrim Natural A.M. and P.M., which launched last June (1"The Tan Sheet" May 15, 2000, p. 7). Heritage pulled original Acutrim formulas from the market after FDA's November request that companies voluntarily halt marketing PPA-containing products. The Acutrim franchise has lost market share in recent years to ephedrine alkaloid-containing supplements

You may also be interested in...



Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned

Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.

Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned

Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.

Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned

Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel